<SEC-DOCUMENT>0001193125-20-250568.txt : 20200922
<SEC-HEADER>0001193125-20-250568.hdr.sgml : 20200922
<ACCEPTANCE-DATETIME>20200922060314
ACCESSION NUMBER:		0001193125-20-250568
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20200922
FILED AS OF DATE:		20200922
DATE AS OF CHANGE:		20200922

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		201187800

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 5
		STREET 2:		20 GEORGE STREET
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		LEVEL 5
		STREET 2:		20 GEORGE STREET
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d848533d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>FORM 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of September, 2020 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia
Therapeutics Limited </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9745;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form 40-F&nbsp;&nbsp; &#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if
the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule
101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by
check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>:
Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which
the registrant is incorporated, domiciled or legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country exchange on which the registrant&#146;s securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been distributed to the registrant&#146;s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on
EDGAR. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp; No&nbsp;&nbsp;&#9745; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If
&#147;yes&#148; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b) </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Kazia Therapeutics Limited</B> <B></B>(Registrant) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Kate Hill </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kate Hill </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company Secretary </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date 22&nbsp;September 2020 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g848533img001.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX RELEASE </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">22&nbsp;September 2020 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>KAZIA ENTERS CLINICAL
COLLABORATION WITH </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DANA-FARBER CANCER INSTITUTE FOR PRIMARY CNS LYMPHOMA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sydney, 22&nbsp;September</B><B> 2020</B> &#150; Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company,
is pleased to announce that it has entered into a collaboration with Dana-Farber Cancer Institute (DFCI) in the United States, to investigate the use of Kazia&#146;s investigational new drug, paxalisib (formerly GDC-0084), in primary central nervous
system (CNS) lymphoma, a potential new indication for the drug. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Key Points </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Lymphoma is a cancer of white blood cells. It occurs in the lymphatic system and can spread almost anywhere in
the body; primary CNS lymphoma (PCNSL) occurs exclusively in the brain and central nervous system </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The PI3K inhibitor class is well validated in lymphoma outside the brain; three of the four FDA-approved PI3K
inhibitors are treatments for forms of lymphoma, but they are assumed ineffective for PCNSL since they cannot cross the blood-brain barrier </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">DFCI will initiate an open-label phase II clinical trial of paxalisib in PCNSL </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The study is expected to recruit up to 25 patients, taking up to 2 years to complete </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Kazia will provide support including study drug and a financial grant </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">This study will be the sixth ongoing clinical trial of paxalisib in brain cancer </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dana-Farber Cancer Institute (DFCI) is a world-leading cancer treatment and research centre, based in Boston, Massachusetts. It is a principal teaching
affiliate of Harvard Medical School and has been designated a Comprehensive Cancer Center by the US National Cancer Institute. DFCI participates in as many as 600 clinical trials at any given time and has been an important contributor to the
development of many important new cancer therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia CEO, Dr James Garner, commented, &#147;this is an exciting new opportunity for the paxalisib
program. We are delighted to support the team at Dana-Farber to explore the potential for paxalisib to benefit patients with PCNSL. Dana-Farber is one of the world&#146;s leading centres of excellence in this disease, so we are immensely fortunate
to be working with them. We are pleased also to see a new and important target added to the broader paxalisib clinical program, and we look forward to seeing the project commence.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia&#146;s financial support to the study will use a portion of the funds contributed by shareholders in the Share Purchase Plan (SPP) conducted in May
2020. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Primary CNS Lymphoma </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lymphoma is a haematological malignancy (blood cancer) that originates from lymphocytes, a type of white blood cell involved in the immune system. PCNSL is a
specific form of the disease that originates in the brain and central nervous system. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Three of the four PI3K inhibitors approved by the US Food and Drug
Administration (FDA) are treatments for various forms of lymphoma, provide a strong validation for PI3K as a target in this disease. Paxalisib is the only PI3K inhibitor in mainstream development with the ability to penetrate the blood-brain
barrier, and as such has a unique rationale for development in PCNSL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PCNSL accounts for approximately 4% of brain tumours, and the incidence is
increasing with time. Patients are typically in their 60s or older, and the disease is slightly more common in men.<SUP STYLE="font-size:85%; vertical-align:top">1</SUP> The mainstays of treatment comprise chemotherapy and radiotherapy, but
recurrence is common and only approximately 30% of patients remain alive five years after diagnosis.<SUP STYLE="font-size:85%; vertical-align:top">2</SUP> Many of the drugs used to treat lymphoma elsewhere in the body are ineffective in PCNSL due to
their inability to cross the blood-brain barrier. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Clinical Trial Design </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dana Farber Cancer Institute will launch a single-arm phase II clinical trial in patients with relapsed or refractory PCNSL, who are resistant to existing
treatments. The primary endpoint will be to assess efficacy via overall response rate (ORR), which measures the ability of paxalisib to shrink tumours. Safety and other efficacy endpoints will also be captured. The study will also examine tissue and
cerebrospinal fluid samples to identify potential predictors of response. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The principal investigator for the study is Dr Lakshmi Nayak, Director of the
CNS Lymphoma Center at Dana-Farber Cancer Institute. Dr Nayak is an Assistant Professor of Neurology at Harvard Medical School and a board-certified neuro-oncologist. Her research interests focus on metastatic brain cancer, glioblastoma, and PCNSL,
and she is extensively published in the field of brain cancer. She has been an investigator for multiple clinical trials of experimental drugs in this disease area. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Commencement of recruitment to the study is expected in early CY2021, but is subject to receiving necessary approvals from FDA and from institutional review
boards. The study will be listed on clinicaltrials.gov closer to the commencement of recruitment. </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">J Rubenstein et al. (2008) <I>Leuk Lymphoma</I> 49(0 1):43-51 </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">MS Shiels et al. (2016) <I>Br J Haematol</I>. 174(3):417-424 </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dana-Farber Cancer Institute </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The CNS Lymphoma Center (CNSLC) at Dana-Farber / Brigham and Women&#146;s Cancer Center is the first centre of its kind in the world dedicated to providing
comprehensive care and research for patients with primary or secondary CNS lymphoma. With the most advanced treatment options available &#151; including surgery, chemotherapy, stem cell transplant, radiation therapy, immunotherapy, and targeted
therapies, and with extensive clinical trial options &#151; CNSLC is uniquely qualified to treat patients with CNS lymphoma and advance the outcome of patients with these tumors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other clinicians at Dana-Farber Cancer Institute are currently involved in clinical trials of paxalisib in other forms of brain cancer. Dr Jose Pablo Leone is
the principal investigator on a phase II clinical trial of paxalisib in combination with Herceptin (trastuzumab) for breast cancer brain metastases (breast cancer that has spread to the brain). Professor Patrick Wen has been centrally involved in
the ongoing phase II study of paxalisib in glioblastoma, and plays a leadership role in the international GBM AGILE study. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Paxalisib Clinical Program
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The initiation of this trial in PCNSL brings the number of ongoing clinical studies of paxalisib in brain cancer to six. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Indication</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Phase</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Sponsor</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Registration</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Glioblastoma</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">II</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Kazia Therapeutics</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">NCT03522298</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DIPG</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">I</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">St Jude Children&#146;s Research Hospital</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">NCT03696355</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Breast Cancer Brain Metastases (with trastuzumab)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">II</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Dana-Farber Cancer Institute</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">NCT03765983</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brain Metastases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">II</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Alliance for Clinical Trials in Oncology</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">NCT03994796</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brain Metastases (with radiotherapy)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">I</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Memorial Sloan-Kettering Cancer Center</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">NCT04192981</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Primary CNS Lymphoma</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">II</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Dana-Farber Cancer Institute</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">(TBD)</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Next Steps </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Recruitment to this study is expected to commence in 1H CY2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia completed recruitment to a phase II clinical trial of paxalisib in newly-diagnosed glioblastoma in February 2020, and interim clinical data was
presented at the AACR Virtual Annual Meeting II in June 2020. Overall survival was calculated at 17.7 months, which compares favourably to an historical figure of 12.7 for temozolomide, the existing FDA-approved standard of care. Kazia expects to
present further data from this study in 2H CY2020, and to conclude the study in early CY2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Our pipeline includes
two clinical-stage drug development candidates, and we are working to develop therapies across a range of oncology indications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead program is
paxalisib (formerly GDC-0084), a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults. Licensed from Genentech in late
2016, paxalisib entered a phase II clinical trial in 2018. Interim data was reported most recently at AACR in June 2020, and further data is expected in 2H 2020. Four additional studies are ongoing in other forms of brain cancer. Paxalisib was
granted Orphan Drug Designation for glioblastoma by the US FDA in February 2018, and Fast Track Designation for glioblastoma by the US FDA in August 2020. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Designation
by the US FDA for DIPG in August 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TRX-E-002-1 (Cantrixil), is a third-generation benzopyran molecule with activity against cancer stem cells and is
being developed to treat ovarian cancer. TRX-E-002-1 has completed a phase I clinical trial in Australia and the United States with the final data expected in the second half of calendar 2020. Interim data was presented most recently at the AACR
conference in June 2020. Cantrixil was granted orphan designation for ovarian cancer by the US FDA in April 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document was authorized for
release to the ASX by James Garner, Chief Executive Officer, Managing Director. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g848533img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g848533img001.jpg
M_]C_X  02D9)1@ ! 0$"6 )8  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M# P,# P,# P,#/_  !$( 'L#%P,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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MZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /A.BBBON#XL**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1NHHH -U&ZBB@ W4;J** /7_ -@@Y_:_\%_]=+W_ -(+FBD_8'_Y._\ !?\
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MN9=Q\K[&!FC-6-6TF[T#5;JPU"UNK&_L9GM[FVN8FAFMI48J\;HP#*ZL""I
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M<^M,1?+967Y6C^Z1_#SGCTYYXJ/J>EK_ (=[7_*YI]<5[\OX]KV_,_57XF_
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MACQ(N[X$Q6EXP\8:M\0O%NJ:]KVH76K:WK5U)>W][<OOFNYY&+.['U)/;@=
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M-[9_ QY[>XMY#'-;R+H1971ARK*0"".00#7+_P#!,O\ ;5\+_P#!6W]CC6O
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MOAZF*==1J+W.6]]$^:^SLWNNVFGH<WBC%%%<AZ08HQ110 8HQ110 8HQ110
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MRI58WC)6:[I]#U;XI?M?>)?B9\5_#_BSR+'2[CPNP;3K:(-)$AW!G+ECEM^
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HV9KFXT6:.*+=97"+EB,#+,H^I%%?T545SU<QG-W:1T4<#&FK)G__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
